Literature DB >> 31430372

Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.

Ester Del Barrio-Tofiño1, Irina Sánchez-Diener1, Laura Zamorano1, Sara Cortes-Lara1, Carla López-Causapé1, Gabriel Cabot1, Germán Bou2, Luis Martínez-Martínez3, Antonio Oliver1.   

Abstract

OBJECTIVES: To evaluate the correlation of O-antigen serotypes with resistance profiles and high-risk clones in a Spanish nationwide survey.
METHODS: Up to 30 consecutive healthcare-associated Pseudomonas aeruginosa isolates were collected during October 2017 from each of 51 hospitals (covering all Spanish regions) with a total of 1445 isolates studied. MICs of 13 antipseudomonal agents and MDR/XDR profiles had been previously determined, as well as whole-genome sequences of 185 representative XDR isolates. O-antigen serotypes (O1-O16) were determined by agglutination using serotype-specific antisera (BioRad). The Pseudomonas aeruginosa serotyper (PAst) program was used for in silico serotyping.
RESULTS: The most frequent serotypes were O6 (17.8%), O1 (15.4%) and O11 (13.3%). In contrast, the most frequent serotype among XDR isolates (17.3%) was O4 (34.1%), distantly followed by O11 (15.9%). Within serotypes, XDR phenotypes were more frequent for O12 (60.0%) and O4 (57.3%). The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (3.6%). Up to 81.6% of XDR ST175 isolates typed O4, whereas 18.4% were non-typeable. O4 genotype was detected in all sequenced (n=55) ST175 isolates. On the other hand, CC235 and ST308 were associated with O11, whereas CC111 was linked to serotype O12.
CONCLUSIONS: O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to colistin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore, after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical antipseudomonal therapies and infection control measures in Spanish hospitals.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31430372     DOI: 10.1093/jac/dkz346

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.

Authors:  Raúl Recio; Mikel Mancheño; Esther Viedma; Jennifer Villa; María Ángeles Orellana; Jaime Lora-Tamayo; Fernando Chaves
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Detection of Pseudomonas aeruginosa Serogroup G Using Real-Time PCR for Novel Target Genes Identified Through Comparative Genomics.

Authors:  Chufang Wang; Qinghua Ye; Yu Ding; Jumei Zhang; Qihui Gu; Rui Pang; Hui Zhao; Juan Wang; Qingping Wu
Journal:  Front Microbiol       Date:  2022-06-24       Impact factor: 6.064

3.  New Sequence Type ST3449 in Multidrug-Resistant Pseudomonas aeruginosa Isolates from a Cystic Fibrosis Patient.

Authors:  Catalina Díaz-Ríos; Marta Hernández; David Abad; Laura Álvarez-Montes; Athanasia Varsaki; David Iturbe; Jorge Calvo; Alain A Ocampo-Sosa
Journal:  Antibiotics (Basel)       Date:  2021-04-23

4.  Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection.

Authors:  Alan S Cross; Sharon M Tennant; Shamima Nasrin; Nicolas Hegerle; Shaichi Sen; Joseph Nkeze; Sunil Sen; Jasnehta Permala-Booth; Myeongjin Choi; James Sinclair; Milagritos D Tapia; J Kristie Johnson; Samba O Sow; Joshua T Thaden; Vance G Fowler; Karen A Krogfelt; Annelie Brauner; Efthymia Protonotariou; Eirini Christaki; Yuichiro Shindo; Andrea L Kwa; Sadia Shakoor; Ashika Singh-Moodley; Olga Perovic; Jan Jacobs; Octavie Lunguya; Raphael Simon
Journal:  BMC Microbiol       Date:  2022-01-06       Impact factor: 3.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.